Purines 2010: Adenine Nucleosides and Nucleotides in Biomedicine.
The Purines 2010: Adenine Nucleosides and Nucleotides in Biomedicine meeting, held in Tarragona, Spain, included topics covering new findings in the field of purinergic signaling and the development of purine-based drugs. This conference report highlights selected presentations on developments in purinerigic signaling, medicinal chemistry, the therapeutic potential of purine-based drugs, and the role of purines and adenosine receptors in neurodegenerative disorders, sickle cell disease, bone homeostasis, pulmonary fibrosis and pain. Investigational drugs discussed include CF-101 (Can-Fite BioPharma Ltd/NIH/Kwang Dong Pharmaceutical Co Ltd/Seikagaku Corp) and denufosol tetrasodium (Cystic Fibrosis Foundation Therapeutics Inc/Inspire Pharmaceuticals Inc).
Sereda
Michal J
MJ
University of Leicester, UK. mjs75@le.ac.uk
D000227:Adenine Nucleotides / Q000627:therapeutic use*; D000241:Adenosine / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D000755:Anemia, Sickle Cell / Q000188:drug therapy / Q000378:metabolism; D001842:Bone and Bones / Q000378:metabolism; D003550:Cystic Fibrosis / Q000188:drug therapy / Q000378:metabolism; D015195:Drug Design; D015507:Drugs, Investigational / Q000627:therapeutic use*; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy / Q000378:metabolism; D019636:Neurodegenerative Diseases / Q000188:drug therapy / Q000378:metabolism; D010146:Pain / Q000188:drug therapy / Q000378:metabolism; D011658:Pulmonary Fibrosis / Q000188:drug therapy / Q000378:metabolism; D011983:Receptors, Purinergic / Q000502:physiology; D015398:Signal Transduction
D000227:Adenine Nucleotides; D015507:Drugs, Investigational; D011983:Receptors, Purinergic; D000241:Adenosine